Pfizer Inc. PFE
28.67
0.26
0.92%
as of 25 Sep
- Market cap
- $161.7B
- P/E
- 37.7×
Follow PFE
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Pfizer Inc. (PFE) Net margin
Pfizer Inc.'s net margin over the twelve months to 30 June 2026 was 6.80%, down 5.6 percentage points from fiscal 2025 (12.4%). Over the past ten years it has ranged from 3.56% (fiscal 2023) to 40.6% (fiscal 2017); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 8.27% and above the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 12.4% | (0.20) |
| FY2024 | 12.6% | 9.06 |
| FY2023 | 3.56% | (27.45) |
| FY2022 | 31.0% | 3.97 |
| FY2021 | 27.0% | 5.05 |
| FY2020 | 22.0% | (17.19) |
| FY2019 | 39.2% | 11.86 |
| FY2018 | 27.3% | (13.23) |
| FY2017 | 40.6% | 26.89 |
| FY2016 | 13.7% | (0.59) |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | −1.65% | (20.24) |
| Mar 2026 | 18.6% | 27.97 |
| Dec 2025 | −9.38% | (30.64) |
| Sep 2025 | 21.3% | 1.40 |
| 42 more quarters | Free account |
Against its own ten years
Low 3.56%
High 40.6%
Ten-year median
22.0%
Current reading's percentile
18
Net margin against peers
| Company | Net margin |
|---|---|
| NVO Novo Nordisk A/S compare | 35.5% |
| AMGN Amgen Inc. compare | 23.0% |
| NVS Novartis AG compare | 22.5% |
| BMY Bristol Myers Squibb Company compare | 18.9% |
| AZN AstraZeneca PLC compare | 17.0% |
| GSK GSK PLC Sponsored ADR compare | 14.6% |
| SNY Sanofi compare | 8.22% |
| PFE Pfizer Inc. | 6.80% |
| GILD Gilead Sciences, Inc. compare | −10.6% |
| Drug Manufacturers General industry median | 8.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on PFE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement